[{"id":"3a5c5d6a-237c-4943-9f23-41234e0aa377","acronym":"","url":"https://clinicaltrials.gov/study/NCT03755804","created_at":"2021-01-18T18:27:48.805Z","updated_at":"2025-02-25T16:37:17.115Z","phase":"Phase 2","brief_title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","source_id_and_acronym":"NCT03755804","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone • dacarbazine • bendamustine • bleomycin • vinblastine • Neupogen (filgrastim) • cyclophosphamide intravenous • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-07"},{"id":"5416351c-6e6b-41af-9e81-7fd2a0e36c13","acronym":"GETUG 13","url":"https://clinicaltrials.gov/study/NCT00104676","created_at":"2021-01-18T00:20:19.559Z","updated_at":"2025-02-25T16:35:55.671Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors","source_id_and_acronym":"NCT00104676 - GETUG 13","lead_sponsor":"UNICANCER","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • ifosfamide • oxaliplatin • etoposide IV • bleomycin"],"overall_status":"Completed","enrollment":" Enrollment 263","initiation":"Initiation: 11/26/2003","start_date":" 11/26/2003","primary_txt":" Primary completion: 03/29/2012","primary_completion_date":" 03/29/2012","study_txt":" Completion: 02/08/2023","study_completion_date":" 02/08/2023","last_update_posted":"2025-02-06"},{"id":"a20ca03c-e4c8-424b-9577-602d1900d998","acronym":"SWENOTECA-ABC","url":"https://clinicaltrials.gov/study/NCT02341989","created_at":"2021-01-18T11:07:54.417Z","updated_at":"2024-07-02T16:35:43.889Z","phase":"Phase 3","brief_title":"Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer","source_id_and_acronym":"NCT02341989 - SWENOTECA-ABC","lead_sponsor":"St. Olavs Hospital","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • etoposide IV • bleomycin"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 04/08/2015","start_date":" 04/08/2015","primary_txt":" Primary completion: 12/01/2035","primary_completion_date":" 12/01/2035","study_txt":" Completion: 12/01/2035","study_completion_date":" 12/01/2035","last_update_posted":"2023-07-06"},{"id":"f263e4c7-8d97-4e67-989f-b832aa084e2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01873326","created_at":"2021-01-18T08:23:43.317Z","updated_at":"2024-07-02T16:35:44.198Z","phase":"Phase 2","brief_title":"Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors","source_id_and_acronym":"NCT01873326","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" AFP","pipe":" | ","alterations":" LDH elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • ifosfamide • etoposide IV • bleomycin • mesna"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-06-30"},{"id":"4b87c7c7-3bac-4f3c-931b-f9da998486ab","acronym":"BREACH","url":"https://clinicaltrials.gov/study/NCT02292979","created_at":"2021-01-18T10:48:37.178Z","updated_at":"2025-02-25T14:57:07.731Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.","source_id_and_acronym":"NCT02292979 - BREACH","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • bleomycin • vinblastine"],"overall_status":"Completed","enrollment":" Enrollment 170","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 06/02/2022","study_completion_date":" 06/02/2022","last_update_posted":"2022-08-19"},{"id":"712abef4-ee9f-449b-a706-9e273acea522","acronym":"","url":"https://clinicaltrials.gov/study/NCT00822120","created_at":"2021-01-18T03:07:31.140Z","updated_at":"2024-07-02T16:36:05.303Z","phase":"Phase 2","brief_title":"S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma","source_id_and_acronym":"NCT00822120","lead_sponsor":"Southwest Oncology Group","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • dacarbazine • Matulane (procarbazine hydrochloride) • bleomycin • vinblastine • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 371","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 04/30/2016","primary_completion_date":" 04/30/2016","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2022-08-18"},{"id":"0c4ed01f-14ce-4638-8fa4-fe09d03ac925","acronym":"","url":"https://clinicaltrials.gov/study/NCT00000954","created_at":"2021-01-29T06:52:47.531Z","updated_at":"2025-02-25T14:22:42.205Z","phase":"Phase 1/2","brief_title":"A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma","source_id_and_acronym":"NCT00000954","lead_sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • vincristine • bleomycin"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 09/01/1996","study_completion_date":" 09/01/1996","last_update_posted":"2021-10-29"},{"id":"d4393a9c-c069-473a-ab37-f7c924576c0d","acronym":"BRAPP2","url":"https://clinicaltrials.gov/study/NCT02298283","created_at":"2021-01-18T10:50:17.525Z","updated_at":"2024-07-02T16:36:27.463Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD","source_id_and_acronym":"NCT02298283 - BRAPP2","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone • Matulane (procarbazine hydrochloride) • bleomycin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 07/09/2020","primary_completion_date":" 07/09/2020","study_txt":" Completion: 07/09/2020","study_completion_date":" 07/09/2020","last_update_posted":"2021-07-26"},{"id":"7d0ad35c-729c-4a9a-9c46-630300efb330","acronym":"","url":"https://clinicaltrials.gov/study/NCT00053352","created_at":"2021-01-18T00:06:05.785Z","updated_at":"2024-07-02T16:36:28.005Z","phase":"Phase 3","brief_title":"Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors","source_id_and_acronym":"NCT00053352","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • etoposide IV • bleomycin"],"overall_status":"Completed","enrollment":" Enrollment 302","initiation":"Initiation: 11/03/2003","start_date":" 11/03/2003","primary_txt":" Primary completion: 10/01/2013","primary_completion_date":" 10/01/2013","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2021-07-13"},{"id":"344a185c-4d14-4622-97e3-9f7082b8a174","acronym":"","url":"https://clinicaltrials.gov/study/NCT01132807","created_at":"2021-01-29T07:00:47.583Z","updated_at":"2024-07-02T16:36:29.143Z","phase":"Phase 2","brief_title":"Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma","source_id_and_acronym":"NCT01132807","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • dacarbazine • Matulane (procarbazine hydrochloride) • bleomycin • vinblastine • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 164","initiation":"Initiation: 05/01/2010","start_date":" 05/01/2010","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2021-06-14"},{"id":"52750e71-c473-47c9-a697-eb60cc06c36f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04139070","created_at":"2021-01-18T20:12:43.297Z","updated_at":"2024-07-02T16:36:41.845Z","phase":"Phase 1","brief_title":"Electrochemotherapy for Non-curable Gastric Cancer","source_id_and_acronym":"NCT04139070","lead_sponsor":"Zealand University Hospital","biomarkers":" CD8 • PD-1 • CD28","pipe":" | ","alterations":" CD28 expression","tags":["CD8 • PD-1 • CD28"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD28 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bleomycin"],"overall_status":"Unknown status","enrollment":" Enrollment 8","initiation":"Initiation: 06/15/2020","start_date":" 06/15/2020","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 07/01/2021","study_completion_date":" 07/01/2021","last_update_posted":"2020-08-20"},{"id":"a5402968-68ab-4b67-9404-aa713ed1bfce","acronym":"(Optimist)","url":"https://clinicaltrials.gov/study/NCT03527628","created_at":"2021-01-18T17:23:16.028Z","updated_at":"2024-07-02T16:36:53.589Z","phase":"Phase 2","brief_title":"OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy","source_id_and_acronym":"NCT03527628 - (Optimist)","lead_sponsor":"King Abdullah International Medical Research Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • dacarbazine • bleomycin • vinblastine • cyclophosphamide intravenous"],"overall_status":"Unknown status","enrollment":" Enrollment 220","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 01/15/2021","primary_completion_date":" 01/15/2021","study_txt":" Completion: 01/15/2022","study_completion_date":" 01/15/2022","last_update_posted":"2019-11-18"},{"id":"6129b8c1-97e8-40ad-bc4c-14d9562b4225","acronym":"","url":"https://clinicaltrials.gov/study/NCT03018626","created_at":"2021-01-18T14:51:23.386Z","updated_at":"2024-07-02T16:37:19.430Z","phase":"Phase 3","brief_title":"R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL","source_id_and_acronym":"NCT03018626","lead_sponsor":"Nanfang Hospital of Southern Medical University","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • bleomycin • cyclophosphamide intravenous • vindesine"],"overall_status":"Unknown status","enrollment":" Enrollment 402","initiation":"Initiation: 07/27/2017","start_date":" 07/27/2017","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2021","study_completion_date":" 01/01/2021","last_update_posted":"2017-07-28"}]